Kamerling
Johannis Paulis Kamerling, Groningen NL
Patent application number | Description | Published |
---|---|---|
20140336140 | METHODS FOR PROVIDING SIALYLATED OLIGOSACCHARIDES - The invention relates to a method for providing analogs of human milk oligosaccharides (HMO), in particular oligosaccharides containing terminal sialic acid. The method comprises the steps of: a) providing a source of non-digestible galactooligosaccharides (GOS) containing at least two terminally bonded β-linked galactose residues; b) providing a sialic acid donor having (α2-3)-sialylated O-glycans; c) contacting said GOS with said sialic acid donor in the presence of an enzyme having trans-sialidase activity in an enzyme reaction mixture; and d) isolating from said enzyme reaction mixture a fraction comprising at least 20 percent by weight of disialylated galactooligosaccharides (di-Sia-GOS) based on the dry matter. | 11-13-2014 |
Johannis Paulus Kamerling, Linschoten NL
Patent application number | Description | Published |
---|---|---|
20120165290 | GLUCOOLIGOSACCHARIDES COMPRISING (ALPHA 1->4) AND (ALPHA 1->6) GLYCOSIDIC BONDS, USE THEREOF, AND METHODS FOR PROVIDING THEM - The invention relates to the field of poly- and oligosaccharides and their nutritional effects. In particular, it relates to the application of α-glucanotransferases in methods for preparing dietary fibers, including prebiotic oligosaccharides, and to novel oligosaccharides obtainable thereby. Provided is a method for producing a mixture of gluco-oligosaccharides having one or more consecutive (α1→6) glucosidic linkages and one or more consecutive (α1→4) glucosidic linkages, comprising contacting a poly- and/or oligosaccharide substrate comprising at least two (α1→4) linked D-glucose units with an ?-glucanotransferase capable of cleaving (α1→4) glucosidic linkages and making new (α1→4) and (α1→6) glucosidic linkages. Also provided are (isolated) gluco-oligosaccharides obtainable thereby, and their application in nutritional and cosmetic compositions. | 06-28-2012 |
Steven Glenn Kamerling, Kalamazoo, MI US
Patent application number | Description | Published |
---|---|---|
20100075996 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS - Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds. | 03-25-2010 |
20100234314 | IDARUBICIN FOR THE TREATMENT OF LYMPHOMA IN A DOG - The present invention relates to a method of treating a lymphoma in a dog comprising administering to a dog in need of such treatment a therapeutically effective amount of idarubicin or a pharmaceutically acceptable salt thereof. | 09-16-2010 |
20120122901 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS - Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds. | 05-17-2012 |